Advertisement

Clinical Rheumatology

, Volume 37, Issue 8, pp 2095–2102 | Cite as

Tuberculosis and systemic lupus erythematosus: a case-control study in Mexico City

  • Pedro Torres-González
  • Juanita Romero-Díaz
  • Miguel Enrique Cervera-Hernández
  • Mario Ocampo-Torres
  • Luis Gerardo Chaires-Garza
  • Ernesto Alejandro Lastiri-González
  • Yemil Atisha-Fregoso
  • Miriam Bobadilla-del-Valle
  • Alfredo Ponce-de-León
  • José Sifuentes-Osornio
Original Article
  • 109 Downloads

Abstract

To determine, among systemic lupus erythematosus patients, factors associated with active tuberculosis. We performed a case-control study, in a tertiary-care center in Mexico City. We defined cases as systemic lupus erythematosus patients with active tuberculosis and matched them 1:1 with systemic lupus erythematosus patients without tuberculosis (controls) by age, date of systemic lupus erythematosus diagnosis, and disease duration. We analyzed clinical variables, lupus disease activity (SLEDAI-2K), and accumulated damage (SLICC/ARC-DI). We performed a nonconditional logistic regression to determine factors associated with tuberculosis. We identified 72 tuberculosis cases among systemic lupus erythematosus patients, 58% were culture confirmed. Thirty-three percent (24/72) were pulmonary only, 47.2% (34/72) extrapulmonary only, and 19.4% both. After adjustment for age, gender, and socioeconomic status, SLEDAI-2K and SLICC/ARC-DI, a 1-year cumulative dose of prednisone ≥ 3 g (odds ratios (OR), 18.85; 95% confidence interval (95% CI), 6.91–51.45) was associated with tuberculosis, and the antimalarial treatment was protective (OR, 0.13; 95% CI, 0.04–0.36). Among systemic lupus erythematosus patients, cumulative dose of prednisone is associated with tuberculosis. Further research is required to elucidate the protective effect of antimalarial drugs for tuberculosis. Preventive strategies must be implemented in patients at risk.

Keywords

Accumulated damage Antimalarial drugs Disease activity Prednisone Systemic lupus erythematosus Tuberculosis 

Notes

Funding

This work was supported by internal funding.

Compliance with ethical standards

Ethics statement

This study was carried out in compliance with the Helsinki Declaration. The Institutional Review Board approval for this study was obtained from the Comité Institucional de Investigación Biomédica en Humanos (reference 1534). All collected data were anonymized before analysis.

Disclosures

None.

References

  1. 1.
    Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365(22):2110–2121.  https://doi.org/10.1056/NEJMra1100359 CrossRefPubMedGoogle Scholar
  2. 2.
    Navarra SV, Leynes MS (2010) Infections in systemic lupus erythematosus. Lupus 19(12):1419–1424.  https://doi.org/10.1177/0961203310374486 CrossRefPubMedGoogle Scholar
  3. 3.
    Shyam C, Malaviya AN (1996) Infection-related morbidity in systemic lupus erythematosus: a clinico-epidemiological study from northern India. Rheumatol Int 16(1):1–3CrossRefPubMedGoogle Scholar
  4. 4.
    Balakrishnan C, Mangat G, Mittal G, Joshi VR (1998) Tuberculosis in patients with systemic lupus erythematosus. J Assoc Physicians India 46(8):682–683PubMedGoogle Scholar
  5. 5.
    Pelaez-Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M, Rodriguez-Amado J, Goycochea-Robles MV, Madariaga M, Zamudio J, Santana N, Cardiel MH, Grupo de Estudio Epidemiologico de Enfermedades Musculo A (2011) Epidemiology of the rheumatic diseases in Mexico A study of 5 regions based on the COPCORD. J Rheumatol Suppl 86:3–8.  https://doi.org/10.3899/jrheum.100951 CrossRefPubMedGoogle Scholar
  6. 6.
    Hou CL, Tsai YC, Chen LC, Huang JL (2008) Tuberculosis infection in patients with systemic lupus erythematosus: pulmonary and extra-pulmonary infection compared. Clin Rheumatol 27(5):557–563.  https://doi.org/10.1007/s10067-007-0741-8 CrossRefPubMedGoogle Scholar
  7. 7.
    Ghosh K, Patwardhan M, Pradhan V (2009) Mycobacterium tuberculosis infection precipitates SLE in patients from endemic areas. Rheumatol Int 29(9):1047–1050.  https://doi.org/10.1007/s00296-009-0903-x CrossRefPubMedGoogle Scholar
  8. 8.
    Prabu V, Agrawal S (2010) Systemic lupus erythematosus and tuberculosis: a review of complex interactions of complicated diseases. J Postgrad Med 56(3):244–250.  https://doi.org/10.4103/0022-3859.68653 CrossRefPubMedGoogle Scholar
  9. 9.
    Doria A, Canova M, Tonon M, Zen M, Rampudda E, Bassi N, Atzeni F, Zampieri S, Ghirardello A (2008) Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev 8(1):24–28.  https://doi.org/10.1016/j.autrev.2008.07.019 CrossRefPubMedGoogle Scholar
  10. 10.
    Tam LS, Li EK, Wong SM, Szeto CC (2002) Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol 31(5):296–300CrossRefPubMedGoogle Scholar
  11. 11.
    Yun JE, Lee SW, Kim TH, Jun JB, Jung S, Bae SC, Kim TY, Yoo DH (2002) The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol 20(2):127–132PubMedGoogle Scholar
  12. 12.
    Sayarlioglu M, Inanc M, Kamali S, Cefle A, Karaman O, Gul A, Ocal L, Aral O, Konice M (2004) Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. Lupus 13(4):274–278CrossRefPubMedGoogle Scholar
  13. 13.
    Wang J, Pan HF, Su H, Li XP, Xu JH, Ye DQ (2009) Tuberculosis in systemic lupus erythematosus in Chinese patients. Trop Dr 39(3):165–167.  https://doi.org/10.1258/td.2008.080379 CrossRefGoogle Scholar
  14. 14.
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E et al (1992) Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus. J Rheumatol 19(11):1820–1821PubMedGoogle Scholar
  15. 15.
    Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288–291PubMedGoogle Scholar
  16. 16.
    Torres-Gonzalez P, Cervera-Hernandez ME, Martinez-Gamboa A, Garcia-Garcia L, Cruz-Hervert LP, Bobadilla-Del Valle M, Ponce-de Leon A, Sifuentes-Osornio J (2016) Human tuberculosis caused by Mycobacterium bovis: a retrospective comparison with Mycobacterium tuberculosis in a Mexican tertiary care Centre, 2000-2015. BMC Infect Dis 16(1):657.  https://doi.org/10.1186/s12879-016-2001-5 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Bijlsma JW, Jacobs JW, Buttgereit F (2015) Glucocorticoids in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 33(4 Suppl 92):S34–S36PubMedGoogle Scholar
  18. 18.
    Cain DW, Cidlowski JA (2017) Immune regulation by glucocorticoids. Nat Rev Immunol 17(4):233–247.  https://doi.org/10.1038/nri.2017.1 CrossRefPubMedGoogle Scholar
  19. 19.
    O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP (2013) The immune response in tuberculosis. Annu Rev Immunol 31:475–527.  https://doi.org/10.1146/annurev-immunol-032712-095939 CrossRefPubMedGoogle Scholar
  20. 20.
    Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF (2015) Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23(5):231–269.  https://doi.org/10.1007/s10787-015-0239-y CrossRefPubMedGoogle Scholar
  21. 21.
    Crowle AJ, May MH (1990) Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3. Antimicrob Agents Chemother 34(11):2217–2222CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Rolain JM, Colson P, Raoult D (2007) Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 30(4):297–308.  https://doi.org/10.1016/j.ijantimicag.2007.05.015 CrossRefPubMedGoogle Scholar
  23. 23.
    Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C (2009) Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 11(4):R109.  https://doi.org/10.1186/ar2764 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Gonzalez Leon R, Garrido Rasco R, Chinchilla Palomares E, Garcia Hernandez FJ, Castillo Palma MJ, Sanchez Roman J (2010) Tuberculosis in a cohort of patients with systemic lupus erythematosus. Reumatol Clin 6(5):256–261.  https://doi.org/10.1016/j.reuma.2009.11.002 CrossRefPubMedGoogle Scholar
  25. 25.
    Merayo-Chalico J, Rajme-Lopez S, Barrera-Vargas A, Alcocer-Varela J, Diaz-Zamudio M, Gomez-Martin D (2016) Lymphopenia and autoimmunity: a double-edged sword. Hum Immunol 77(10):921–929.  https://doi.org/10.1016/j.humimm.2016.06.016 CrossRefPubMedGoogle Scholar
  26. 26.
    Leeds IL, Magee MJ, Kurbatova EV, del Rio C, Blumberg HM, Leonard MK, Kraft CS (2012) Site of extrapulmonary tuberculosis is associated with HIV infection. Clin Infect Dis 55(1):75–81.  https://doi.org/10.1093/cid/cis303 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Kerkhoff AD, Meintjes G, Burton R, Vogt M, Wood R, Lawn SD (2016) Relationship between blood concentrations of hepcidin and anemia severity, mycobacterial burden, and mortality among patients with HIV-associated tuberculosis. J Infect Dis 213(1):61–70.  https://doi.org/10.1093/infdis/jiv364 CrossRefPubMedGoogle Scholar
  28. 28.
    Mittal S, Agarwal P, Wakhlu A, Kumar A, Mehrotra R, Mittal S (2016) Anaemia in systemic lupus erythematosus based on iron studies and soluble transferrin receptor levels. J Clin Diagn Res 10(6):EC08–EC11.  https://doi.org/10.7860/JCDR/2016/17930.7961 PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Hernandez-Cruz B, Ponce-de-Leon-Rosales S, Sifuentes-Osornio J, Ponce-de-Leon-Garduno A, Diaz-Jouanen E (1999) Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases. A case-control study. Clin Exp Rheumatol 17(1):81–87PubMedGoogle Scholar
  30. 30.
    Gaitonde S, Pathan E, Sule A, Mittal G, Joshi VR (2002) Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis 61(3):251–253CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  • Pedro Torres-González
    • 1
  • Juanita Romero-Díaz
    • 2
  • Miguel Enrique Cervera-Hernández
    • 1
  • Mario Ocampo-Torres
    • 2
  • Luis Gerardo Chaires-Garza
    • 3
  • Ernesto Alejandro Lastiri-González
    • 3
  • Yemil Atisha-Fregoso
    • 3
  • Miriam Bobadilla-del-Valle
    • 1
  • Alfredo Ponce-de-León
    • 1
  • José Sifuentes-Osornio
    • 3
  1. 1.Department of Infectious DiseasesInstituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico CityMexico
  2. 2.Department of Immunology and RheumatologyInstituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico CityMexico
  3. 3.Department of MedicineInstituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico CityMexico

Personalised recommendations